Advertisement


Daniel J. George, MD, on RCC: Results From the Alliance A031203 CABOSUN Trial

2018 Genitourinary Cancers Symposium

Advertisement

Daniel J. George, MD, of Duke University Medical Center, discusses study findings on cabozantinib vs sunitinib for previously untreated patients with advanced renal cell carcinoma of intermediate or poor risk, in a subgroup analysis of progression-free survival and objective response rates (Abstract 582).



Related Videos

Bladder Cancer
Immunotherapy

Gregory R. Pond, PhD, on Urothelial Cancer: Advance in Prognosis

Gregory R. Pond, PhD, of McMaster University, discusses a new six-factor prognostic model for patients with advanced urothelial carcinoma receiving post platinum atezolizumab (Abst...

Bladder Cancer

John J. Coen, MD, on Bladder Cancer: Results From the NRG/RTOG 0712 Trial

John J. Coen, MD, of 21st Century Oncology, discusses phase II study findings on selective bladder preservation with twice-daily radiation plus fluorouracil/cisplatin or daily radi...

Prostate Cancer

Robert G. Bristow, MD, PhD, on Prostate Cancer: Keynote Lecture

Robert G. Bristow, MD, PhD, of Manchester Cancer Research Centre, discusses germline and somatic mutations; new ways to generate biomarkers that may describe tumor complexity; and ...

Bladder Cancer
Immunotherapy

Thomas Powles, MD, on Urothelial Carcinoma: Results From the IMvigor211 Trial

Thomas Powles, MD, of Barts Cancer Institute, discusses phase III study findings on atezolizumab vs chemotherapy in platinum-treated locally advanced or metastatic urothelial carci...

Prostate Cancer

Paul L. Nguyen, MD, on Prostate Cancer: Abstract Roundup

Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he chaired on prostate cancer, which included discussion of daily vs weekly image-guided radiotherapy;...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.